Do Commensal Microbes Stoke the Fire of Autoimmunity?

June 1, 2019

When immunologist Rachel Caspi began studying an inflammatory eye disease called autoimmune uveitis in the mid-1980s, she had to inoculate mice with a protein found in the mammalian retina to spark the disease. Injecting interphotoreceptor retinoid-binding protein (IRBP) along with an immune-stimulating compound called an adjuvant into the animals’ bloodstream prompted the mice’s own T cells to attack their eyes. That led to inflammation, tissue damage, and eventual blindness.

Spotlight

Maxwell Biotech Group

Maxwell Biotech Group (MBG) is a development partner and financial resource for biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Our unique business model can add value to our partners’ pipelines and provide a commercialization path to one of the most lucrative emerging markets. MBG relies on an experienced international team of managers and financial and industry experts, with offices in Moscow, Boston and San Diego.

Other Infographics
news image

Building the European biotech sector with world-class science and innovation

Infographic | August 5, 2021

Europe continues to be a powerhouse of science and innovation. The region maintains a clear lead over China, the United States, and the rest of the world in terms of the quality and quantity of its science. For example, Europe is home to 43 of the global top 100 life-science universities, while the United States has 34. Europe is a powerhouse in scientific publishing as well, with roughly twice the output of the United States and three times that of China.Europe also leads in terms of quality, as measured by the number of citations for its publications. More than 40,000 biotech patents have been granted in Europe since 2015, although the region’s 3 percent CAGR in patent approvals between 2015 and 2019 lagged behind that of the United States (4 percent) and was a fraction of China’s (14 percent).Despite Europe’s strength in science and innovation, translation remains the biggest challenge. Translation of science into companies is stagnant. The distribution of newly funded biotechs remains unchanged across geographies over the last six years, and Europe accounts for only 25 percent of new biotechs. Future success will depend on improving the translation of research into new companies, raising more capital, and building entrepreneurial talent.

Read More
news image

The COVID-19 pandemic has swept the globe, yet many people still do not understand how it affects the body

Infographic | April 16, 2020

The COVID-19 pandemic has swept the globe, yet many people still do not understand how it affects the body. This infographic shows the events that occur following SARS-CoV-2 infection

Read More
news image

Next-Gen Genetics: Cancer Therapies Create Investment Prospects

Infographic | August 12, 2022

The field (gene therapy) is not standing still, it’s evolving rapidly. If we have this discussion again in 18 months’ time, I don't know what we’ll be using then.

Read More
news image

Designing Genetic Circuit

Infographic | April 13, 2020

Near the turn of the millennium, James Collins and Stanislas Leibler independently undertook rather similar projects: design what would become synthetic biology’s seminal genetic circuits. And they came up with strikingly similar action plans—use E. coli to pair promoters with repressors that control one another’s behavior.

Read More
news image

What Paraspeckles Can Teach Us About Basic Cell Biology

Infographic | December 1, 2019

Discovering a new type of subnuclear body taught me how pursuing the unexpected can lead to new insights—in this case, about long noncoding RNAs and liquid-liquid phase separation in cells.

Read More
news image

Global Bioinformatics Market

Infographic | August 23, 2021

As per the study, the global Bioinformatics market was valued at $3.4 billion in 2013, and it is expected to reach $12.8 billion by 2020. The market is expected to grow at a CAGR of 21.2% during 2014-2020

Read More

Spotlight

Maxwell Biotech Group

Maxwell Biotech Group (MBG) is a development partner and financial resource for biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Our unique business model can add value to our partners’ pipelines and provide a commercialization path to one of the most lucrative emerging markets. MBG relies on an experienced international team of managers and financial and industry experts, with offices in Moscow, Boston and San Diego.

Events